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REKABENTUK DAN PENILAIAN TABLET PELEPASAN TERKAWAL 
MATRIKS GLIKLAZID  
 
ABSTRAK 
 
Tablet pelepasan terkawal matriks gliklazid disediakan dengan menggunakan 
bahan-bahan polymer, iaitu, HPMC, Kollidon SR, Carbopol dengan Xanthan 
gum, Eudragit RSPO dan Eudragit RLPO. HPMC, Kollidon SR dan Carbopol 
dengan Xanthan gum mampu merencat pelepasan gliklazid daripada tablet 
matriks dalam corak yang bergantung pada kepekatan, tetapi kadar perencatan 
adalah berbeza di antara polimer. Sebaliknya, pelepasan drug daripada tablet 
yang mengandungi Eudragit RSPO dan Eudragit RLPO, tidak bergantung pada 
kepekatan polimer yang digunakan dan tidak ada corak yang konsisten 
diperhatikan. Di antara pelbagai jenis polimer dan kepekatan yang dikaji, profil 
pelepasan tablet matriks yang mengandungi 6% HPMC (formulasi H2) didapati 
setara dengan tablet Diamicron MR, seperti yang ditunjukkan oleh nilai-nilai 
“similarity factor” dan “difference factor”. Di samping itu, pelepasan drug 
formulasi H2, tidak dipengaruhi oleh perubahan dalam pH tetapi dipengaruhi 
secara drastic oleh perubahan dalam kadar pengacauan. Sebelum kajian in 
vivo, kaedah isokratik HPLC-UV yang mudah, sensitive dan spesifik untuk 
penentuan kepekatan gliklazid dalam plasma arnab telah dibangunakan dan 
divalidasikan. Kaedah ekstrasi cecair-cecair digunakan dalam rawatan sample. 
Kaedah esei ini digunakan untuk kajian farmakokinetik gliclazide, 
membandingkan formulasi H2 dan Diamicron MR sebagai produk rujukan. 
Empat arnab digunakan dalam penilaian in vivo. Tidak ada perbezaan yang 
signifikan secara statistic di antara formulasi F2 dan Diamicron MR dalam nilai-
 xx
niali Tmax, Cmax dan AUC. Secara kesimpulan, kadar dan jumlah gliklazid 
yang diserap untuk formulasi H2 adalah standing dengan Diamicron MR.       
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DESIGN AND EVALUATION OF PROLONGED RELEASE GLICLAZIDE 
MATRIX TABLETS 
 
ABSTRACT 
 
The prolonged release gliclazide matrix tablets were prepared using polymeric 
materials, namely, HPMC, Kollidon SR, Carbopol with Xanthan gum, Eudragit 
RSPO and Eudragit RLPO. HPMC, Kollidon SR and Carbopol with Xanthan 
gum were able to retard gliclazide release from matrix tablets in a concentration 
dependent manner, but the rate of retardation differed among the polymers. On 
the other hand, drug release from matrix tablets containing Eudragit RSPO and 
Eudragit RLPO, was independent of the amount of polymer used, and no 
consistent drug release pattern was observed. Among the various types of 
polymers and concentrations studied, the dissolution profile of matrix tablets 
containing 6% HPMC (formulation H2) was found to be similar to that of 
Diamicron MR tablets as indicated by the values of similarity factor and 
difference factor. In addition, the drug release of formulation H2, was not 
affected by changes in pH but affected drastically by changes in the stirring 
rate. Prior to the in vivo study, a simple, sensitive, and specific isocratic HPLC-
UV method for the determination of gliclazide concentration in rabbit plasma 
was developed and validated. A liquid-liquid extraction method was used in the 
sample treatment. The assay method was used in the pharmacokinetic study of 
gliclazide, comparing formulation H2 and Diamicron MR as a reference 
product. Four rabbits were used in the in vivo evaluation. There was no 
statistically significant difference between formulation F2 and Diamicron MR in 
the values of Tmax, Cmax and AUC. In conclusion, the rate and extent of 
 xxii
absorptions of gliclazide for formulation H2 was comparable with Diamicron 
MR.       
 1  
                                                      CHAPTER 1  
INTRODUCTION 
 
1.1 ORAL CONTROLLED RELEASE DOSAGE FORM 
Oral drug delivery system is the most popular route, which is due in part to the 
ease of administration and to the fact that gastrointestinal physiology offers more 
flexibility in dosage form design than most other routes (Gupta and Robinson, 
1992). There is a plethora of oral controlled release products in the market place. 
For example, in 1998, the U.S Food and Drug Administration (FDA) approved 90 
oral controlled release products. From 1998 to 2003, FDA approved an additional 
of 29 new drug applications that used controlled release technologies and 12 of 
them were based on matrix systems (Liu et at., 2006).  
                                                                                                            
Development of oral controlled release dosage forms of a given drug involves 
optimization of the dosage form characteristics within the inherited constrains of 
the gastrointestinal physiology. Controlled release delivery systems have added 
advantages over immediate release dosage form. These include reduction of 
dosing frequency by administering the drug once or twice a day (Hayashi et al., 
2005). Since the frequency of drug administration is reduced, patient compliance 
can be improved, and drug administration can be more convenient (Nokhodchi et 
al., 2002) due to reduction of gastrointestinal side effects (Hosny, 1996). Also 
1.2 ADVANTAGES AND DISADVANTAGES OF ORAL CONTROLLED 
RELEASE DELIVERY SYSTEM 
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causes less fluctuation of plasma drug level and leads to more uniform drug effect 
and lesser total dose. 
 
On the other hand, controlled release dosage forms have some disadvantages 
which include, generally higher cost, relatively poor in vitro/in vivo correlation, 
unpredictable and even reduced bioavailability and subjected to increased first-
pass metabolism for certain drugs. In order to exert control over the rate of the 
drug release, as well as movement of the dosage from through the gastrointestinal 
tract, a number of factors such as motility, pH, ionic strength of luminal content 
and differential absorption must be considered (Gupta and Robinson, 1992).   
                     
1.3 VARIOUS APPROACHES TO ACHIEVE CONTROLLED RELEASE 
DRUG DELIVERY 
 
Various techniques have been used in the formulation of controlled release 
products. In general, controlled release formulations can be divided into different 
categories based on the mechanism of drug release (Venkatraman et al, 2000). 
 
1.3.1 Ion exchange resins  
Ion exchange resins are cross-linked water-insoluble polymers carrying ionizable 
functional groups. The resins have been used in various pharmaceutical 
applications, primarily for taste masking and controlled release systems. In tablet 
formulations, ion exchange resins have been used as disintegrants because of 
their swelling ability. It forms irreversible complex with ionizable drugs upon 
prolonged exposure of the drug to the resin. A resin bound-drug is removed when 
 3  
appropriate ions are in contact with ion-exchanged groups. The area and length of 
diffusion pathway, and the amount of cross-linked polymer in the resin moiety 
governs the rate of drug release. Sriwongjanya and Bodmeier (1988) investigated 
the effect of ion exchange resins as release modifiers in matrix formulations 
containing oppositely charged drugs and they concluded that addition of ion 
exchange resins to HPMC-matrices significantly modified the release of oppositely 
charged drug molecules, because a complex formed between the drug and resin 
retarded the drug release.  
 
1.3.2 Dissolution controlled release  
This type of controlled release involves two processes, the detachment of drug 
molecules from the surface of their solid structure to the adjacent liquid interface, 
followed by their diffusion from the interface into the bulk liquid medium. The rate 
of dissolution and the amount dissolved per unit of time from this system can be 
calculated using Noyes-Whitney equation (1897). Colo et al. (2002) investigated 
the effect of poly-ethylene oxide in the release profile of metformin hydrochloride. 
They found that a combination of acrylic acid polymer (mainly Eudragit) with PEO 
could sustain the release of metformin when administered orally.    
 
1.3.3 Diffusion controlled release 
In this type of controlled release system, the active ingredient diffuses through the 
polymeric material. There are mainly reservoir and matrix systems. 
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1.3.3 (a)  Reservoir system  
It consists of a core (the reservoir) and coating membrane (the diffusion barrier). 
The active ingredient diffuses from the reservoir through the coating membrane. 
For a reservoir system where the drug depot is surrounded by a polymeric 
hydrogel membrane, Fick's first law of diffusion can be used to describe drug 
release through the membrane (Lin and Metters, 2006). 
 
1.3.3 (b) Matrix system 
A matrix system consists of active and inactive ingredients, that are 
homogeneously dispersed and mixed in the dosage form. It is by far the most 
commonly used oral controlled release technology and the popularity of the matrix 
systems can be attributed to several factors which will be discussed in the later 
section. The release from matrix type formulations governed by Fick’s first law of 
diffusion. 
                                                        
                     Eq1.1 
 
J is flux, or rate of diffusion, while Q is the amount diffused per unit of time t, and D 
is diffusion coefficient.  
 
 
 
 
J= dQt          =  -  D dC 
 dt dx 
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1.4. ADVANTAGES OF MATRIX SYSTEM   
Unlike reservoir and osmotic systems, products based on matrix design can be 
manufactured using conventional processes and equipments. Secondly, 
development cost and time associated with the matrix system generally are 
viewed as variables, and no additional capital investment is required. Lastly, a 
matrix system is capable of accommodating both low and high drug loading and 
active ingredients with a wide range of physical and chemical properties. 
 
1.5 LIMITATIONS OF THE MATRIX SYSTEMS 
As with any technology, matrix systems come with certain limitations. First, matrix 
systems lack flexibility in adjusting to constantly changing dosage levels as 
required by clinical study outcome. When new dosage strength is deemed 
necessary, more often than not a new formulation and thus additional resources 
are expected. Furthermore, for some products that require unique release profiles 
(dual release or delayed plus extended release), more complex matrix-based 
technologies such as layered tablets are required. 
 
1.6 TYPES OF MATRIX SYSTEMS 
The matrix system can be divided into two categories depending on the types of 
retarding agent or polymeric materials. 
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1.6. (a) Hydrophobic matrix system   
This is the only system where the use of polymer is not essential to provide 
controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes (Zhou et al, 1998; Vergote et 
al, 2001;  Hayashi et at, 2005), glycerides (Yu Ksel et al, 2003), fatty acids, and 
polymeric materials such as ethyl cellulose, methyl cellulose (Makhija and Vavia. 
2002; Crowley et al., 2004) and acrylate copolymer (Azarmi et al., 2002; Krajacic 
and Tucker. 2003). To modulate drug release, it may be necessary to incorporate 
soluble ingredients such as lactose into formulation. The presence of insoluble 
ingredient in the formulations helps to maintain the physical dimension of 
hydrophobic matrix during drug release. As such, diffusion of active ingredient  
from the system is the release mechanism (Kincl et al., 2004), and the 
corresponding release characteristic can be described by Higuchi equation known 
as square root of time release kinetic (Higuchi, 1963). The square root of time 
release profile is expected with a porous monolith, where the release from such 
system is proportional to the drug loading. In addition, hydrophobic matrix systems 
generally are not suitable for insoluble drug because the concentration gradient is 
too low to render adequate drug release. As such, depending on actual ingredient 
properties or formulation design, incomplete drug release within the 
gastrointestinal transit time is a potential risk and need to be delineated during the 
development. With the growing needs for optimization of therapy, matrix systems 
providing programmable rates of delivery become more important. Constant rate 
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delivery always has been one of the primary targets of controlled release system 
especially for drug with narrow therapeutic index (Liu et at., 2006).   
 
1.6. (b) Hydrophilic matrix system 
The primary rate limiting ingredients of hydrophilic matrix are polymers that would 
swell on contact with aqueous solution and form a gel layer on the surface of the 
system. When the release medium (i.e. water) is thermodynamically compatible 
with a polymer, the solvent penetrates into the free spaces between 
macromolecular chains. The polymer may undergo a relaxation process, due to 
the stress of the penetrated solvent, so that the polymer chains become more 
flexible and the matrix swells. This allows the encapsulated drug to diffuse more 
rapidly out of the matrix. On the other hand, it would take more time for drug to 
diffuse out of the matrix since the diffusion path is lengthened by matrix swelling. 
Moreover, it has been widely known that swelling and diffusion are not the only 
factors that determine the rate of drug release (Sujja-areevath et al., 1998). For 
dissolvable polymer matrix, polymer dissolution is another important mechanism 
that can modulate the drug delivery rate. While either swelling or dissolution can 
be the predominant factor for a specific type of polymers, in most cases drug 
release kinetics is a result of a combination of these two mechanisms (Tahara et 
al., 1995). The presence of water decreases the glassy-rubbery temperature (for 
HPMC from 184°C to below 37°C), giving rise to transformation of glassy polymer 
to rubbery phase (gel layer). The enhanced motility of the polymeric chain favours 
the transport of dissolved drug. Polymer relaxation phenomena determine the 
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swelling or volume increase of the matrix. Depending on the polymer 
characteristics, the polymer amount in the rubbery phase, at the surface of the 
matrix, could reach the disentanglement concentration; the gel layer varies in 
thickness and the matrix dissolves or erodes. The concentration at which 
polymeric chains can be considered disentangled was demonstrated to 
correspond to an abrupt change in the rheological properties of the gel. Boniferoni 
et al. (1995) showed a relationship between rheological behaviour of HPMC gels 
and their erosion rate, conforming that the polymer-polymer and polymer-water 
interaction are responsible for the gel network structure and its sensitivity to 
erosion. In turn, they affect drug release rate in the case of poorly soluble drugs.  
 
Swelling controlled release systems are based upon these principles. Due to the 
viscoelastic properties of the polymer which are enhanced by the presence of 
cross-linked network, anomalous penetrant transport can be observed. This 
behaviour is bound by pure Fickian diffusion and case II transport. Therefore, 
transport can be reduced to three driving forces. The penetrant concentration 
gradient, polymer concentration gradient and osmotic force behavior are observed 
as a result of polymer network. Appropriate polymer can counterbalance normal 
Fickian diffusion by hindering the release of embedded drug, leading to an 
extended period of drug delivery, and possibly zero-order release (Cox et al., 
1999).  
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Drug release from swellable matrix tablets can be affected by glassy-rubbery 
transition of polymer (as a result of water penetration into the matrix where 
interaction among water, polymer and drug or fillers is considered as the primary 
factor for release control) and the various formulation variables, such as polymer 
grade and type, drug to polymer ratios, drug solubility, drug and polymer particle 
sizes, compaction pressure and presence of additives or excipients in the final 
formulation. Lotfipour et al. (2004) investigated the effect of various polymers, 
fillers, and their concentration on the release rate of atenolol form polymeric 
matrix. They concluded that, the release rate and mechanism of atenolol releases 
from hydrophobic and hydrophilic matrices are mainly controlled by the drug to 
polymer ratio. The results also showed that an increase in the concentration of 
fillers resulted in an increase in the release rate of the drug from matrices and 
hydrophilicity or hydrophobicity of the fillers had no significant effect on the release 
profile. Regarding the mechanism of release, the results showed that in most 
cases the drug release was controlled by both diffusion and erosion depending on 
the polymer type and concentration. On the other hand, incorporation of water 
soluble fillers like polyethylene glycol, lactose and surfactant into gel forming 
matrices can improve phenomenon of insufficient drug release, because these 
excipients can enhance the penetration of the solvent or water into the inner part 
of matrices, resulting in drug release from the matrices (Genc¸ et al., 1999; 
Nokhodchi et al., 2002). 
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1.7. POLYMERS USED IN HYDROPHILIC MATRICES 
Hydrogel polymers were much investigated in literature on basis of drug release 
and release mechanism from hydrophilic matrix tablets as well as pellets. HPMC 
polymers achieve considerable attention due to their unique properties, and they 
can display good compression characteristics, including when directly 
compressed. They are nontoxic and can accommodate high level of drug loading, 
and also having adequate swelling properties that allows rapid formation of an 
external gel layer which retards or plays a major role in controlling drug release. 
Furthermore, HPMC polymers are well known as pH-independent materials, this 
advantage enable them to withstand fluctuations of pH induce by intra and inter-
subject variations of both gastric pH and gastrointestinal transit time. They have 
been used alone or in combination in formulation of matrix tablets, therefore the 
hydrophilic gel forming matrix tablets are extensively used for oral extended 
release dosage forms due to their simplicity, cost effectiveness and reduction of 
the risk of systemic toxicity which happens as a result of dose dumping (Sung et 
al., 1996; Huang et al., 2004). Soliman et at. (2003) investigated the release of 
diclofenac sodium from a mixture of HPMC, Carbopol 940, and lactose as water 
soluble fillers. The results showed that the combination of hydrogels retarded the 
drug better than single polymer.   
 
The principal advantage of HPMC matrix formulations is the drug release rates are 
generally independent of processing variables such as compaction pressure, drug 
particle size, increasing of initial granulation liquid and incorporation of lubricants 
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(Lapidus and Lordi, 1968; Nochochi et al., 2002). The relationship between particle 
size, tensile strength and the viscosity grade of HPMC was complicated. At 
smaller particle size, an increase in the viscosity grade of HPMC resulted in a 
reduction in the tensile strength of its compacts. However, at the large particle 
size, the tensile strength of HPMC compacts decreased with an increase in 
viscosity grade. For HPMC K100M, there was an increase in tensile strength 
(Nokhodchi et al., 1995). The combination of HPMC and HPC at different ratios 
was investigated. Increasing the HPMC-HPC ratio increased both the particle size 
of granules and the tablet hardness (Ebube et al., 1997). The drug release of 
HPMC matrix tablets was slightly influenced by type and concentration of diluents, 
but the viscosity grade of the polymer did not affect the release mechanism 
(Vueba et al., 2004).   
 
Ishikawa et at. (2000) reported an increase in crushing strength of tablets made of 
Macrogol 6000 and HPMC, due to an increase in compression force during 
tableting stage and the dissolution of formulated tablet was significantly affected 
by increasing HPMC concentration.             
 
Huang et al., (2004) developed once daily propranolol extended release tablets 
using HPMC polymer as a retarding agent. The mechanism of the drug release 
from HPMC matrix tablet followed non-Fickian diffusion, while the in vivo 
absorption and in vitro dissolution showed a linear relationship. 
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Other polymers used in hydrophilic matrix preparations include poly ethylene oxide 
(Sriwongjanya and Bodmeier., 1998; Maggia et al., 2003), hydroxypropyl cellulose 
(Ferrero et al., 1997) and hydroxyl ethyl cellulose.  
 
Xanthan gum (XG) was widely used as a thickening agent in food industries, but 
recently introduced in pharmaceutical formulations (Talukdar and Kinget. 1995; 
Ntawukulilyayo et al., 1996; Talukdar et al., 1996; Tobyn et al., 1996; Talukdar and 
Kinge. 1997; Talukdar et al., 1998; Helton et al., 2004; Santos et al., 2004; Santos 
et al., 2005; Veiga-Santos et al., 2005). It is a high molecular weight extracellular 
heteropolysaccharide, produced by fermentation with the gram-negative bacterium 
Xanthamonas campestris. XG shows excellent swelling properties and the 
swelling of the XG polymer matrix shows a square root of time dependence 
whereas drug release is almost time independent (Talukdar and Kinget, 1995).  
 
Carbopol is a derivative of polyacrylic acid. It is a synthetic, high molecular weight, 
crosslinked polymer. It is readily hydrates, absorbs water and swell. In addition, its 
hydrophilic nature and highly crossliked make it a potential candidate and has 
been used in controlled release drug delivery systems (Khan and Jiabi, 1998; 
Wong et al., 1999; Juang and Storey, 2003; Ikinci et al., 2004; Tapia and 
Villafuerte, 2004). In the case of tablets formulated with Carbopol polymer, the 
drug is entrapped in the glassy rubbery core in the dry state. It forms a gelatinous 
layer upon hydration. However, this gelatinous layer is significantly different 
structurally from the traditional matrix tablets. The hydrogel is not entangled chains 
 13  
of polymer, but discrete microgel made up of many polymer particles in which the 
drug is dispersed. The crosslinked network enables the entrapment of drug in the 
hydrogel domains. Since these hydrogels are not water soluble they do not 
dissolve, and erosion in the manner of linear polymer does not occur. Rather, 
when the hydrogel is fully hydrated, osmotic pressure from within works to break 
up the structure, essentially by sloughing off discrete pieces of the hydrogel. This 
hydrogel remains intact, and the drug continues to diffuse through the gel layer at 
a uniform rate (Khan and Jiabi, 1998).     
 
It is well recognized that key formulation variables are matrix dimension and 
shape, polymer level and molecular weight, as well as drug loading and solubility. 
Other factors such as tablet hardness, type of inactive ingredients and processing 
normally play secondary roles. The choice of manufacturing process such as 
direct blending or granulation typically des not affect product performance 
significantly, although exception does exist. In general, processing and scale-up 
associating with hydrophilic matrices are more robust than other controlled release 
systems. 
 
1.8 COMPARISON OF HIGUCHI WITH ZERO-ORDER RELEASE          
MECHANISMS  
Drug release from matrix tablets becomes progressively slower with time (Higuchi, 
1963). This is in contrast to the ideal situation in which the drug is released from 
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the tablets at the same rate throughout the release period. Higuchi profile is 
compared with the ideal release pattern (zero-order release profile) in Figure 1.1  
 
The reason for the attenuation of the drug release rate in Higuchi profile is 
illustrated in Figure 1.2. When a matrix tablet is placed in the dissolution medium, 
the initial drug release occurs from the tablet superficial layer and, consequently, 
the release rate is relatively fast. As time passes, the external layers of the tablet 
become depleted of the drug and water molecules must travel through long, 
tortuous channels to reach the drug remaining in the deeper layer of the tablet. 
Similarly, the drug solution that is formed within the tablet must diffuse through 
long capillaries to reach the external dissolution medium.  The primary reason for 
continuously decreasing rate of drug release is the more the matrix swells, the 
longer the diffusion pathlength required for the drug to come out. Therefore, any 
mechanism that lessens the time–dependent increase in the diffusion pathlength 
would reduce the attenuation of the dissolution (Talukdar et al., 1996; Pather et al., 
1998).  
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Figure 1.1 Comparison of (a)  
(a) (b) 
Figure 1.1 Comparison between (a) Higuchi and (b) zero-order release profiles. 
                  (Adapted from Pather et al. 1998)  
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Initial stage                             Final stage 
 
 
Figure 1.2 Diagrammatic representation of drug release according to Higuchi    
model 
                       (Adapted from Pather et al., 1998) 
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1.9 GLICLAZIDE 
Gliclazide, 1-(4methylbenenesulphonyl) 3-(3azabicyclo [3.3.o] octyl) urea, is a 
second generation sulphonylurea oral hypoglycemic agent used in the treatment of 
non-insulin-dependant diabetes mellitus (NIDDM). It improves defective insulin 
secretion and may reverse insulin resistance observed in patients with NIDDM or 
known as type two diabetes. These actions are reflected in blood glucose level 
which is maintained during short and long term administrations, and is comparable 
with that achieved with other sulphonylurea agents (Palmer and Brogden, 1993). 
 
Gradually accumulating evidence suggests that gliclazide may be useful in 
patients with diabetes retinopathy, due to its hematological actions, and that 
addition to insulin therapy enables insulin dosage to be reduced (Schernthaner, 
2003). 
 
Gliclazide is an effective agent for the treatment of the metabolic disorder 
associated with NIDDM and may have the added advantage of potentially slowing 
the progression of diabetic retinopathy. These actions, together with its good 
tolerability and low incidence of hypoglycemia, allow gliclazide to be well placed 
within the array of oral hypoglycemic agents available for the control of NIDDM. 
 
1.9.1 Pharmacodynamic  
Gliclazide reduces blood glucose levels in patients with NIDDM by correcting both 
defective insulin secretion and peripheral insulin resistance. Un-stimulated and 
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stimulated insulin secretions from pancreatic ß cells are increased following the 
administration of gliclazide, with both first and second phases of secretion being 
affected. This occurs via binding of gliclazide to specific receptor on pancreatic ß 
cells which results in a decrease in potassium efflux and causes depolarization on 
the cell. Subsequently, calcium channels open, leading to an increase in 
intracellular calcium and induction of insulin release. In addition, gliclazide 
increases the sensitivity of ß cells to glucose (Palmer and Brogden, 1993). 
 
Gliclazide may have extra pancreatic effect which restores peripheral insulin 
sensitivity, such as decreasing hepatic glucose production, and increasing glucose 
clearance and skeletal muscle glycogen synthesis activity. These effects do not 
appear to be mediated by effect on insulin receptor number, affinity or function. 
There is some evidence that gliclazide improves defective hematological activity in 
patients with NIDDM (Riccio et al., 1996).  
 
1.9.2 Pharmacokinetic properties 
Oral absorption of gliclazide is similar in patients and healthy volunteers, but there 
is intersubject variation in time to reach peak plasma concentrations (tmax). Ages 
related differences in plasma peak concentrations (Cmax) and tmax, have been 
observed. A single oral dose of 40 to 120 mg of gliclazide results in a Cmax of 2.2 to 
8.0 µg/ml within 2 to 8 hours. Tmax and cmax are increased after repeated gliclazide 
administration. Steady state concentration is achieved after 2 days administration 
of 40 to 120 mg of gliclazide. Gliclazide has low volume of distribution (13 to 24L) 
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in both patients and healthy volunteers due to its high protein binding affinity (85 to 
97%) (Najib et al., 2002). The elimination half-life (t1/2) is about 8.1 to 20.5 hr in 
healthy volunteers and patients after administration of 40 to 120 mg orally. 
Moreover, its plasma clearance is 0.78 L/h (13 ml/min). It is extensively 
metabolized to 7 metabolites and excreted in urine therefore renal insufficiency 
has no effect in pharmacokinetic of gliclazide.  
 
The variability in absorption of gliclazide could be related to its early dissolution in 
the stomach leading to more variability in the absorption in the intestine (Delrat et 
al., 2002). This process resulted in low bioavailability of the conventional dosage 
forms. The use of solubilizing agents like PEG 400 was reported to increase the 
bioavailability of gliclazide in its oral dosage forms (Hong et al., 1998). Also 
gliclazide was included with α-cyclodextrin or β-cyclodextrin (Winters. et al., 1997; 
Maria et al., 1998). 
 
1.9.3 Dosage and administration  
Gliclazide is administrated for the treatment of NIDDM which know as type two in 
patient who failed to respond to dietary restriction. The drug is administered in 
doses range from 40 to 320 mg/day as tablets once to three times daily. Recently, 
modified release formulations containing 20 mg or 30 mg of gliclazide has been 
developed to obtain a better predictable release of active principle (Delrat et al., 
2002; Miwa et al., 2004). 
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1.10 PROBLEM STATEMENT 
At present, patients have to take one or more doses of conventional or sustained 
release gliclazide tablets, to maintain normal plasma glucose levels. Currently, the 
gliclazide tablets available in the market have not yet attained the physiological 
goal of providing constant plasma glucose levels over an extended period of time 
to meet the basal needs between meals and during the night. If there was a 
formulation of gliclazide that could provide adequate control of glucose level for an 
extended period of time without any hypoglycaemic symptoms (Crepaldi and 
Fioretto, 2000), patients could be relived from the necessity of taking 1-4 tablets of 
80 mg of gliclazide daily. Such a formulation would be a helpful not only to improve 
the patients’ conditions and convenience but also to reduce the risk of prevalence 
of other diseases associated with diabetes mellitus. 
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Figure 1.3 Chemical structure 
                     of gliclazide            
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Currently, a lot of researches are carried out to prepare prolonged release 
gliclazide tablets with pharmacokinetic characteristics suited to the circadian 
glycemic profile of type two diabetes. This approach will minimize the 
complications associated with diabetes mellitus (Al-kassas et al., 2007). Diamicron 
MR (30 mg gliclazipe) is available but very expensive. The development of a 
generic version of gliclazide will reduce the price of drug and make the drug more 
affordable to the patients.  
 
1.11 SCOPE OF THE PRESENT STUDY  
The aims of the present study were to design and evaluate prolonged release 
gliclazide matrix tablets. 
 
The study was carried out in the following stages. 
1.   Development and in vitro evaluation of gliclazide matrix tablets.    
2. Development of HPLC-UV method for quantification of gliclazide 
concentration in rabbit plasma.     
3.  In vivo evaluation of gliclazide matrix tablets using rabbits
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CHAPTER 2 
PREPARATION OF PROLONGED RELEASE 
GLICLAZIDE MATRIX TABLETS 
 
2.1 INTRODUCTION 
Tablet is one of the most common and popular oral pharmaceutical dosage 
forms. Oral ingestion has long been the most convenient and commonly 
employed route of drug delivery due to its ease of administration, least aseptic 
constrain and flexibility in the design of the dosage form. Normally, a tablet 
contains a single dose of one or more active substances with excipients (such 
as diluents, binders, disintegrating agents, glidents and lubricants), and is 
usually obtained by compressing uniform volume of particles using a tableting 
machine, to provide a single rigid body of defined mechanical strength. Tablets 
can exist in many geometrical shapes. They are usually circular solid cylinders, 
the end surface of which are flat or convex and the edges of which may be 
beveled. Most recently, there are even the development of multiparticulate 
dosage forms into compressed tablet to overcome the high production cost of 
encapsulating them into hard gelatin capsules (Marshall and Rudnick, 1990; 
Santos et al., 2004)      
 
It is well known that modified release dosage forms may offer one or more 
advantages over immediate release formulation of the same drug. The design 
of modified release drug product is usually intended to optimize therapeutic 
regimen by providing slow and continuous delivery of drug over the entire 
dosing interval, and also to increase patient compliance (Gupta and Robinson, 
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1992). There are many ways to design modified release dosage form for oral 
administration. These include film coated pellets, tablets or capsules to more 
sophisticated and complicated delivery systems such as somatically driven 
system, system of controlled release by ion exchange mechanism, system 
using the three dimensional printing technology and system using electrostatic 
deposition technology (Abdul and Podar, 2004).  
 
Some of the common controlled release matrix delivery systems are in the 
forms of tablets, pellets and granules, where the drug is uniformly dissolved or 
dispersed throughout the polymer matrix. Many researches have been carried 
out to investigate the drug release mechanisms and effects of polymer 
concentration on the release rate of drug from both the hydrophilic and 
hydrophobic matrices (Ford et al., 1987; Ford et al., 1991; Nokhodchi et al., 
1995; Tahara et al., 1995; Sung et al., 1996; Mosquera et al., 1996). For 
example, the use of hydrophilic polymers, in particular cellulose derivatives in 
the formulation of pharmaceutical product, due to their gel-forming ability in 
aqueous medium (Ford et al., 1991). It is reported that the hydration rate of 
cellulose ether polymers depends mainly on the nature of the substituent 
present and the degree of the substitution (Roy and Rohera, 2002).  In addition, 
the penetration of the dissolution medium into the cellulose matrix formulation 
depends also on the type of fillers used (Sako et al., 2002; Lotfipour et al., 
2004). On the other hand, the release rate from hydroxypropyl methylcellulose 
(HPMC) matrices is influenced by the concentration and viscosity grade of the 
polymer in the formulation (Campos-Aldrete et al., 1997; Ebube et al., 1997; 
Samani et al., 2003). However, the major disadvantage associated with HPMC 
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matrices was that the release of drug did not follow a time-independent kinetics 
(Ford et al., 1985; Rao and Devi, 1988).  
 
Most of the above mentioned works on the fabrication of modified release 
dosage forms utilized wet granulation method to increase the uniformity of drug 
distribution in the final product, densify the material, enhance the flow rate,  
facilitate volumetric dispensing, reduce dust and improve the appearance of the 
product. In addition, other advantages of wet granulation include preventing 
segregation of powder mix and enhancing hydrophobic surface to be more 
hydrophilic. Despite of all these advantages, wet granulation has 
disadvantages such as loss of material during various processing stages and 
inactivating active constituents that are affected by moisture (Parikh, 1997). 
 
The aim of this study was to formulate matrix tablets of gliclazide with a 
controlled drug release over a 12-hour period. For this purpose, HPMC, 
Carbopol 940, Xanthan gum, Kollidon SR, and Eudragits (RSPO and RLPO), 
were chosen as the matrix forming polymeric materials. The influence of 
polymer type and concentration on the physical properties and dissolution of 
the tablets were investigated. Moreover, the effects of pH of the dissolution 
medium and stirring rate on drug release as well as the release mechanism of 
a selected formulation were examined. 
 
 
 
 
